Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
65
天
Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen
作者
Jean-Yves Blay; Sylvain Lamure; Waisse Waissi; Marie-Pierre Sunyach; Haifa Bahri; Philippe Rey; Catherine Chassagne-Clement; Emmanuelle Nicolas-Virelizier; Amine Belhabri; Yann Guillermin; Pierre Biron; Catherine Sebban; Thierry Philip; Claire Cropet; Hervé Ghesquieres; Anne-Sophie Michallet展开收起
作者单位
Centre Léon Bérard, 28, rue Laennec, Lyon 69008, France; Service d’Hématologie, CHLS, Pierre-Bénite, France展开收起
95
天
Diagnostic pitfalls and unmet needs in neuroendocrine neoplasms: The added value of collegial expert pathology review through the national TENpath network
作者
Matthieu Tihy; Jean-Yves Scoazec; Serge Guyétant; Mohamed-Amine Bani; Céline Bazille; Geneviève Belleannée; Christian Boissy; Camille Boulagnon-Rombi; Aurélie Cazes; Aurélie Charissoux; Marie-Pierrette Chenard; Marie Danjoux; Camille Darcha; Laurent Doucet; Charlotte Dufour; Antonin Fattori; Anne Guyot; Valérie Hervieu; Marie-Françoise Heymann; Catherine Julié; Thibault Kervarrec; Cosmin Lazaroiu; Emmanuelle Leteurtre; Laurent Martin; Stéphanie Patouraux; Flora Poizat; Nicolas Poté; Agathe Régnier; Benjamin Rivière; Magali Svrcek; Benoît Terris; Jérôme Cros; Anne Couvelard展开收起
作者单位
Université Paris-Cité, Service d′Anatomie Pathologique, ENETS Center of Excellence, Hôpital Bichat (AP-HP), Paris, France; Service de Pathologie, Gustave Roussy Cancer Center, Villejuif, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; Service d′anatomie pathologique et Plateforme de génétique moléculaire des cancers, Hôpital Trousseau, CHRU, UMR INRAE ISP 1282, université de Tours, Tours, France; Service d’Anatomie Pathologique, CHU, Caen, France; Service d’Anatomie Pathologique, CHU, Bordeaux, France; Laboratoire Central d′Anatomie et de Cytologie Pathologiques, Hôpital Pasteur, CHU, Nice, Université Côte d′Azur, Nice, France; Laboratoire de Pathologie, CHU, Reims, France; Service d’Anatomie Pathologique, CHU, Limoges, France; Service d’Anatomie Pathologique, CHU, Strasbourg, France; Service d’Anatomie Pathologique, Oncopole, Toulouse, France; Service d′Anatomie et Cytologie Pathologiques, CHU, Clermont-Ferrand, France; Service d’Anatomie Pathologique, Hôpital Morvan, CHRU, Brest, France; Service d’Anatomie Pathologique, CHU, Lille, France; Service d’Anatomie Pathologique, ENETS Center of Excellence, GHU Est, Hospices Civils de Lyon, Lyon, France; Institut de Cancérologie de l’Ouest, Département de Pathologie Tissulaire et Moléculaire, Saint-Herblain, France; Service d’Anatomie Pathologique, Hôpital Ambroise Paré (AP-HP), Boulogne-Billancourt, France; Service d’Anatomie Pathologique, CHU, Dijon, France; Service d’Anatomie Pathologique, ENETS Center of Excellence, IPC NET Center, Institut Paoli-Calmettes, Marseille, France; Service d’Anatomie Pathologique, CHU, Rouen, France; Service d’Anatomie Pathologique, CHU, Montpellier, France; Université Paris-Cité, Service d’Anatomie Pathologique, Hôpital Saint Antoine (AP-HP), Paris, France; Université Paris-Cité, Service d’Anatomie Pathologique, Hôpital Cochin (AP-HP), Paris, France; Université Paris-Cité, Service d’Anatomie Pathologique, ENETS Center of Excellence, Hôpital Beaujon (AP-HP), Clichy, France; Nantes Université, CNRS, UMR6286, US2B, Nantes, France; Université de Reims Champagne-Ardenne, MEDYC, France; Université de Lille, CNRS, Inserm, CHU Lille, UMR9020-U1366 – UPJV, Lille, France展开收起
44
天
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors
作者
Roberta Scafetta; Raffaella Troiano; Alessandra Guarino; Carla Gullotta; Cristina Fiore; Luisana Sisca; Elena Speziale; Arianna Travisani; Fernando Zannino; Giovanni Miraglia; Marco Donato; Simone Foderaro; Fabio Venuti; Francesco Antonio Vilardi; Valentina Ricozzi; Michele Iuliani; Sonia Simonetti; Silvia Cavaliere; Alessio Cortellini; Annalisa La Cesa; Andrea Di Mattia; Michela Lombardo; Martina Angelone; Andrea Botticelli; Simone Scagnoli; Simona Pisegna; Carmen Criscitiello; Rebecca Pedersini; Caterina Sposetti; Elisa Tiberi; Giuliana D’Auria; Matteo Vergati; Marco Mazzotta; Roberta Caputo; Annarita Verrazzo; Maria Grazia Rossino; Ornella Garrone; Federica Domati; Claudia Piombino; Federica Gatti; Lorena Filomeno; Teresa Arcuri; Federica Puce; Federica Riva; Michela Palleschi; Marianna Sirico; Marta Piras; Luigia Stefania Stucci; Delia De Lisi; Paolo Orsaria; Antonella Grasso; Edy Ippolito; Sara Ramella; Luca Visani; Lorenzo Livi; Stefania Gori; Luigi Rossi; Icro Meattini; Barbara Tagliaferri; Orazio Caffo; Ilaria Portarena; Azzurra Irelli; Elisabetta Cretella; Camillo Porta; Giampaolo Bianchini; Maria Agnese Fabbri; Ugo De Giorgi; Patrizia Vici; Angela Toss; Fiorella Ruatta; Michelino De Laurentiis; Federica Villa; Rossana Berardi; Mauro Minelli; Vittorio Altomare; Claudio Vernieri; Giuseppe Curigliano; Alessandra Chirco; Sara D’Alessandro; Bruno Vincenzi; Giuseppe Tonini; Daniele Santini; Francesco Pantano展开收起
作者单位
Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, Rome 00128, Italy; Medical Oncology Unit, Santa Rosa Hospital, Department of Oncology and Hematology, Strada Sammartinese snc, Viterbo 01100, Italy; Division of Medical Oncology, “G. Martino” University Hospital, Via Consolare Valeria 1, Messina 98124, Italy; Hospital Pharmacy Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy; Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy; Medical Oncology Unit, Azienda Ospedaliero-Universitaria Sant’Andrea, Via di Grottarossa, Rome 1035–1039, Italy; Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, Pieve Emanuele, Milan 20072, Italy; Breast Medical Oncology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, Milan 20089, Italy; Medical Oncology Department, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Dana-Farber/Partners CancerCare, Boston, MA, USA; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Medical Oncology, Università Politecnica delle Marche, AOU delle Marche, Ancona, Italy; Department of Medical Oncology, Medical Oncology Unit, Sandro Pertini Hospital, Rome, Italy; Department of Systems Medicine, 'Tor Vergata' University, Rome, Italy; Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Pascale, Naples, Italy; Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan 20122, Italy; Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy; UOSD Sperimentazioni di fase IV, IRCCS Istituto Nazionale Tumori Regina Elena, Via Elio Chianesi 53, Rome 00144, Italy; Medical Oncology Unit, ICS Maugeri IRCCS, Pavia, Italy; Department of Clinical and Molecular Medicine, Sapienza University of Rome, Policlinico Umberto I, Viale Regina Elena 324, Rome 00161, Italy; Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Interdisciplinary Department of Medicine, University of Bari “A. Moro”, and Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; Medical Oncology Unit, Santa Chiara Hospital, APSS Trento, Italy; Department of Breast Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Department of Radiation Oncology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy; Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Radiation Oncology Unit & Breast Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy; Department of Experimental and Clinical Biomedical Sciences “M. Serio”, University of Florence, Florence, Italy; Medical Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; UOC of Oncology, ASL Latina, Formia, Italy; Department of Radiation Oncology (MAASTRO), GROW Research Institute for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands; Center of Medical Science, University of Trento, Trento, Italy; Medical Oncology Unit, Policlinico Universitario Tor Vergata, Rome, Italy; Medical Oncology Unit, Department of Oncology, “Giuseppe Mazzini” Hospital, AUSL 04 Teramo, Teramo 64100, Italy; Medical Oncology Unit, Ospedale di Bolzano, Bolzano, Italy; Università Vita-Salute San Raffaele, Milan, Italy; Department of Experimental Medicine, University of Salento, Lecce, Italy; Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; Medical Oncology, Oncology Department, ASST Lecco, Lecco 23900, Italy; UOC Oncologia, Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy; European Institute of Oncology, IRCCS, Milan, Italy; ASST Papa Giovanni XXIII, SC Oncologia, Bergamo 24127, Italy; Department of Medical-Surgical Sciences and Biotechnologies, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy展开收起
100
天
Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial
作者
Maria E. Cabanillas; Naifa L. Busaidy; Mark Zafereo; Priyanka C. Iyer; Jennifer R. Wang; Sarah Hamidi; Renata Ferrarotto; Suyu Liu; Gary B. Gunn; Michael Spiotto; Anna Lee; Anastasios Maniakas; Maria Gule-Monroe; Michelle D. Williams; S. Mohsen Hosseini; Victoria E. Banuchi; Mimi I. Hu; Matthew Ning; Ramona Dadu展开收起
作者单位
The University of Texas MD Anderson Cancer Center, Houston, TX, United States展开收起
31
天
Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe
作者
Sarah Hersey; Haydar Celik; Steven Rosen; Christopher Scott; Peter Keeling; Laura Joglekar; Mark Lawler展开收起
作者单位
Johnston Cancer Research Centre, Queen’s University Belfast, School of Medicine, Dentistry & Biomedical Sciences, Belfast, Ireland, UK; Bristol Myers Squibb, Lawrenceville, NJ, USA; Wyss Institute, Harvard, Boston, MA, USA; Future Medicines Institute, Queen’s University Belfast, Belfast, Ireland, UK; Diaceutics PLC, Belfast, Ireland, UK展开收起
98
天
Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial
作者
Alexander Rühle; Alina Krause; Rachel L. O'Connell; John Simes; Michael Michael; Bernard Mark Smithers; Rebecca K.S. Wong; Karin Haustermans; Nils H. Nicolay; Trevor Leong; Florian Lordick展开收起
作者单位
Department of Radiation Oncology, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Medicine II, University of Leipzig Medical Center, Leipzig, Comprehensive Cancer Center Central Germany, Leipzig, Germany; Department of Oncology and University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, Leipzig, Germany; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Surgery, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; Department of Radiation Oncology, Peter MacCallum Cancer Centre, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Radiation Oncology, University of Toronto, Toronto, Canada展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天